MedPath

Effect of Ruji formula combined with shuowang moxibustion on postoperative immune function and circulating tumor cells (DNA) in patients with TNBC

Not Applicable
Recruiting
Conditions
breast cancer
Registration Number
ITMCTR2100004774
Lead Sponsor
Foshan hospital of traditional Chinese medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

1. Patients who met the diagnostic criteria of triple negative breast cancer;
2. After standardized treatment in accordance with the guidelines and specifications for breast cancer diagnosis and treatment of China Anti Cancer Association (2015 Edition), the patients with triple negative breast cancer in stage 0-III were in a tumor free state;
3. Aged from 18 to 70 years;
4. ECOG score: 0-1;
5. The expected survival time was more than 9 months;
6. Informed consent to participate in this study, signed informed consent, expected good compliance, follow-up.

Exclusion Criteria

1. Patients with other malignant tumors or immune system diseases (such as AIDS, rheumatism, severe infection, etc.);
2. Previously found to be allergic to drugs contained in Ruji formula and shuowang moxibustion ointment;
3. The skin condition is poor, unable to accept the treatment of shuowang moxibustion;
4. Pregnant women
5. Patients with bone marrow, liver, kidney, heart, lung and immune dysfunction;
6. 3 months before the detection of immune function received treatment that may affect immune function;
7. Other clinical trials were conducted at the same time.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Relapse-free survival;
Secondary Outcome Measures
NameTimeMethod
Overall survival rate;
© Copyright 2025. All Rights Reserved by MedPath